Search
-
Usages de substances de synthèse en France et en Europe
(Therapie, 2020)Article de revue -
Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis
(Orphanet J Rare Dis. vol. 15, n° 1, pp. 141, 2020)Article de revueOpen access -
DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus
(Drug Safety. vol. 43, n° 8, pp. 767-774, 2020)Article de revue -
Benefit-Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit-Risk Models Applied to Vaccines
(Drug Safety. vol. 43, n° 11, pp. 1089-1104, 2020)Article de revueOpen access -
Medicine misuse: A systematic review and proposed hierarchical terminology
(British Journal of Clinical Pharmacology, 2020-12-08)Article de revue -
Risk of bradyarrhythmia related to ticagrelor: a systematic review and meta-analysis
(Pharmacological Research. pp. 105089, 2020)Article de revue -
Safety Profile of Drugs for Advanced Melanoma: A Report Based on 2008 to 2018 United States Food and Drug Administration Data
(British Journal of Clinical Pharmacology, 2020-12-08)Article de revue -
Reduced reporting of neuropsychiatric adverse events with tumor necrosis factor alpha inhibitors for hidradenitis suppurativa: caution before concluding for risk reduction
(Journal of the European Academy of Dermatology and Venereology. vol. 34, n° 8, pp. e430-e431, 2020)Article de revue -
Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)
(Drug Safety. vol. 43, n° 11, pp. 1105-1120, 2020)Article de revueOpen access -
Using Discretely Integrated Condition Event Simulation To Construct Quantitative Benefit-Risk Models: The Example of Rotavirus Vaccination in France
(Clinical Therapeutics. vol. 42, n° 10, pp. 1983-1991 e2, 2020)Article de revueOpen access